SavedAdd your journal

Journals / Akdeniz Tıp Dergisi / 2018 / Cilt: 4 - Sayı: 1

The Helical Tomotherapy Experience on Radiotherapy of The Helical Tomotherapy Experience on Radiotherapy of Glioblastoma Multiforme

Glioblastoma Multiforme Glioblastoma Multiforme Radyoterapisinde Helikal Tomoterapi Deneyimi

Eda KÜÇÜKTÜLÜ
Pages
48–53
Publication Date
2022-10-11
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

The overall survival was 14.8 months.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: The standard treatment of Glioblastome Multiforme (GBM) is surgical resection followed by chemoradiotherapy and adjuvant temozolamide.
📊
Key Findings & Data:It also offers application of Simultaneous Integrated Boost (SIB).Material and Methods: Among our 12 patients, 7 had a diagnosis of GBM whereas 3 of them were anaplastic oligoastrocytoma and 2 of them were diagnosed radiologically as high-grade glial tumor.
💡
Conclusion & Impact:The overall survival was 14.8 months.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Objective: The standard treatment of Glioblastome Multiforme (GBM) is surgical resection followed by chemoradiotherapy and adjuvant temozolamide. Intensity Modulated Radiotherapy (IMRT) offer an advantage in terms of reducing the dose to critical normal structures and a reduced dose to the normal brain. It also offers application of Simultaneous Integrated Boost (SIB).Material and Methods: Among our 12 patients, 7 had a diagnosis of GBM whereas 3 of them were anaplastic oligoastrocytoma and 2 of them were diagnosed radiologically as high-grade glial tumor. In all patients, 60 Gy SIB-IMRT with concomitant Temozolomide was used. Results: In post treatment Magnetic Resonance Imaging (MRI), 8 patients had no recurrence whereas 2 patients showed partial response and in 2 patients there was no response at all. After a median follow-up period of 12 months, 3 patients survived disease free, and 9 patients were expired. The overall survival was 14.8 months. Median progression free survival was 4.4 months. The mean dose received by the brain stem was 12.90 Gy and 12.72 Gy for the optic chiasm.Conclusion: High doses can be given while protecting critical tissues with SIB-IMRT.

Özet

Amaç: Glioblastome Multiforme'de (GBM) standart tedavi cerrahi rezeksiyon sonrası eşzamanlı kemoradyoterapi ve adjuvant temozolamiddir. Intensity Modulated Radiotherapy (IMRT) normal dokuları koruyarak tümöre daha yüksek dozlar verebilme ve Simultaneous Integrated Boost (SIB) imkanı sunar. Gereç ve Yöntemler: 12 beyin tümörlü hastanın yedisi glioblastome multiforme, üçü anaplastik oligoastrositom, ikisi radyolojik olarak yüksek gradlı glial tümördü. Hastalara toplam 60 Gy SIB-IMRT yapıldı. Tüm hastalara eşzamanlı temozolomid verildi.Bulgular: Tedavi sonrası Manyetik Rezonans Görüntüleme (MRG) sonuçları tam rezeksiyon yapılan 8 hastada rekürrens olmadığını, 2 hastada parsiyel yanıt, 2 hastada da hiç yanıt alınmadığını gösterdi. Grad 3 hematolojik toksisite 1 hastada görüldü. 12 aylık ortanca takip süresi sonunda üç hasta hastalıksız yaşarken 9 hasta eksitus oldu. Toplam yaşam süresi 14,8 ay ve ortanca progresyonsuz sağkalım 4,4 ay idi. Beyin sapının aldığı ortalama doz 12,90 Gy iken optik kiazma için 12,72 Gy'dir. Sonuç: Optik kiazma ve beyin sapı gibi kritik organlara verilen dozlar düşürülürken, hedef volüme verilen doz SIB-IMRT ile arttırılmıştır.

🔖

Cite This Article

KÜÇÜKTÜLÜ, E. (2022). The Helical Tomotherapy Experience on Radiotherapy of The Helical Tomotherapy Experience on Radiotherapy of Glioblastoma Multiforme. Akdeniz Tıp Dergisi, Cilt: 4 - Sayı: 1, 48–53. https://ajindex.com/articles/434446

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (10)

  1. Laperriere N, Zuraw L, Cairncross G; Cancer Care Ontario Practice Guidelines Initiative Neuro-Oncology Disease Site Group. Radiotherapy for newly diagnosed malignant glioma in adults a systematic review. Radiat and Oncol 2002; 64: 259-73
  2. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E, Mirimanoff RO; European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups; National Cancer Institute of Canada Clinical Trials Group. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastome. N Eng J Med 2005; 352: 987-96
  3. Hegi ME, Diserens A, Gorlia T, Hamou MF, de Tribolet N, Weller M, Kros JM, Hainfellner JA, Mason W, Mariani L, Bromberg JE, Hau P, Mirimanoff RO, Cairncross JG, Janzer RC, Stupp R. MGMT gene silencing and benefi t from temozolomide in glioblastome. N Eng J Med 2005; 352: 997-1003
  4. Garden AS, Maor MH,Yung WK, Bruner JM,Woo SY,Moser RP, Lee YY. Outcome and patterns of failure following limited-volume irradiation for malignant astrocytomas. Radother Oncol 1991; 20: 99-110
  5. Wallner KE, Galicich JH, Krol G, Arbit E, Malkin MG. Patterns of failure following treatment for glioblastome multiforme and anaplastic astrocytoma. Int J Radiat Oncol Biol Phys 1989; 16: 1405-9
  6. Fuller CD, Choi M, Forthuber B, Wang SJ,Rajagiriyil N, Salter BJ, Fuss M. Standart fractionation intensity modulated radiation therapy (IMRT) of primary and recurrent glioblastome multiforme. Radiat Oncol 2007; 2007;14;2:26
  7. MacDonald SM, Ahmad S, Kachris S, Vogds BJ, DeRouen M, Gittleman AE, DeWyngaert K, Vlachaki MT. Intensity modulated radiation therapy versus three-dimensional conformal radiation therapy for the treatment of high grade glioma: A dosimetric comparison. J Appl Clin Med Phys 2007; 8: 47-60
  8. Aherne NJ, Benjamin LC, Horsley PJ, Silva T, Wilcox S, Amalaseelan J, Dwyer P, Tahir AM, Hill J, Last A, Hansen C, McLachlan CS, Lee YL, McKay MJ, Shakespeare TP. Improved outcomes with intensity modulated radiation therapy combined with temozolomide for newly diagnosed glioblastome multiforme. Neu Res Int 2014: 1-5
  9. Welsh JS, Patel RR, Ritter MA, Harari PM, Mackie TR, Mehta MP. Helical tomotherapy: An innovative technology and approach to radiation therapy. Technol Cancer Res Treat 2002; 1(4): 311-6
  10. Burnet NG, Adams EJ, Fairfoul J, Tudor GS, Hoole AC